Global Cell Therapy Biomanufacturing Market 2022-2028
June 2022
80
About the Report
About the Report
Cell therapies aims to introduce new, healthy cells into a patient's body, to replace the diseased or missing ones. Manufacturing them involves collecting a specific set of cells from the blood, modifying them to produce a more vigorous attack on a patient's cancer cells, and then reinjecting them into the patient. The global cell therapy biomanufacturing market is likely to register a CAGR of over 8.8% with an incremental growth of USD 4 billion during the forecast period 2022-2028.
The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global cell therapy biomanufacturing market. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, growth rate and market segments. This study also provides an analysis of the impact of the COVID-19 crisis on the cell therapy biomanufacturing industry.
This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the application, and region. The global market for cell therapy biomanufacturing can be segmented by application: bone repair, cancer, cardiovascular diseases, neurological disorders, skeletal muscle repair, others. In 2021, the skeletal muscle repair segment made up the largest share of revenue generated by the cell therapy biomanufacturing market. Cell therapy biomanufacturing market is further segmented by region: Asia Pacific, Europe, North America, MEA (Middle East and Africa), Latin America. North America was the largest contributor to the global cell therapy biomanufacturing market in 2021.
By application:
- bone repair
- cancer
- cardiovascular diseases
- neurological disorders
- skeletal muscle repair
- others
By region:
- Asia Pacific
- Europe
- North America
- MEA (Middle East and Africa)
- Latin America
The report also provides analysis of the key companies of the industry and their detailed company profiles including Bone Therapeutics S.A., Caladrius Biosciences, Inc., Iovance Biotherapeutics, Inc., Lonza Group AG, Merck KGaA, Novartis AG, Regen BioPharma, Inc., Regeneus Ltd., The Bristol-Myers Squibb Company (BMS), among others.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
Historical & Forecast Period
This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.
Scope of the Report
- To analyze and forecast the market size of the global cell therapy biomanufacturing market.
- To classify and forecast the global cell therapy biomanufacturing market based on application, region.
- To identify drivers and challenges for the global cell therapy biomanufacturing market.
- To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global cell therapy biomanufacturing market.
- To identify and analyze the profile of leading players operating in the global cell therapy biomanufacturing market.
Why Choose This Report
- Gain a reliable outlook of the global cell therapy biomanufacturing market forecasts from 2022 to 2028 across scenarios.
- Identify growth segments for investment.
- Stay ahead of competitors through company profiles and market data.
- The market estimate for ease of analysis across scenarios in Excel format.
- Strategy consulting and research support for three months.
- Print authentication provided for the single-user license.
Products
Products
Cell Therapy Biomanufacturing,
Companies
Bone Therapeutics S.A., Caladrius Biosciences Inc., Iovance Biotherapeutics Inc., Lonza Group AG, Merck KGaA, Novartis AG, Regen BioPharma Inc., Regeneus Ltd., The Bristol-Myers Squibb Company (BMS)
Table of Contents
Table of Contents
TABLE OF CONTENTS
FIGURES AND TABLES
PART 1. INTRODUCTION
- Report description
- Objectives of the study
- Market segment
- Years considered for the report
- Currency
- Key target audience
PART 2. METHODOLOGY
PART 3. EXECUTIVE SUMMARY
PART 4. MARKET OVERVIEW
- Introduction
- Drivers
- Restraints
- Impact of COVID-19 pandemic
PART 5. MARKET BREAKDOWN BY APPLICATION
- Bone repair
- Cancer
- Cardiovascular diseases
- Neurological disorders
- Skeletal muscle repair
- Others
PART 6. MARKET BREAKDOWN BY REGION
- Asia Pacific
- Europe
- North America
- MEA (Middle East and Africa)
- Latin America
PART 7. KEY COMPANIES
- Bone Therapeutics S.A.
- Caladrius Biosciences, Inc.
- Iovance Biotherapeutics, Inc.
- Lonza Group AG
- Merck KGaA
- Novartis AG
- Regen BioPharma, Inc.
- Regeneus Ltd.
- The Bristol-Myers Squibb Company (BMS)
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
DISCLAIMER
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.